Article ID Journal Published Year Pages File Type
8228645 International Journal of Radiation Oncology*Biology*Physics 2011 5 Pages PDF
Abstract
Gemcitabine at low doses combined with cisplatin is a potent radiosensitizer effective in patients with LAHN cancer. The recommended Phase II dose is 10 mg/m2 of gemcitabine and 30 mg/m2 of cisplatin with an acceptable tolerability profile.
Keywords
Related Topics
Physical Sciences and Engineering Physics and Astronomy Radiation
Preview
Weekly Gemcitabine and Cisplatin in Combination With Radiotherapy in Patients With Locally Advanced Head-and-Neck Cancer: Phase I Study
Authors
, , , , ,